Strona główna・Stock List・Krystal Biotech Inc

Krystal Biotech Inc

Closed

SectorHealthcare

322.67 0.11

Buy Sell

Overview

Share price change

24h

Current

Min

319.45

Max

327.74

Key metrics
By Trading Economics
Income	-1.2M 55M
Sales	2.9M 119M
P/E Sector Avg	45.697 68.51
EPS	1.79
Profit margin	45.938
Employees	295
EBITDA	2.9M 66M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+23.76% upside

Dividends
By Acuity
Next Earnings	2 lis 2026

Market Stats
By TradingEconomics
Market Cap	-1.1B 9.3B
Previous open	322.56
Previous close	322.67

News Sentiment

By Acuity

86%

14%

323 / 340 Ranking in Healthcare

Krystal Biotech Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

5 sie 2026, 19:52 UTC

Krystal Biotech Inc shares are lower today, breaking a trend of higher closes. Broader market sentiment is cautious following ADP's weak employment report.

4 sie 2026, 20:04 UTC

News

Citigroup raised its price target on Krystal Biotech to $386, contributing to upward movement in shares despite earlier session pullbacks.

3 sie 2026, 23:06 UTC

Krystal Biotech Inc shares are higher in after-market hours, recovering from an earlier dip. Broader market sentiment improved following stronger-than-expected economic data.

31 lip 2026, 23:06 UTC

Krystal Biotech Inc is trading lower in after-market hours amid volatility, with no specific news identified to explain the movement.

30 lip 2026, 19:39 UTC

Krystal Biotech Inc shares are higher today, maintaining gains since Wednesday's close. The stock remains above its 20-day moving average despite a slight pullback.

29 lip 2026, 20:04 UTC

Krystal Biotech shares are lower amid a broader market decline, influenced by significant drops in major U.S. stocks ahead of the Federal Reserve's announcement.

28 lip 2026, 20:03 UTC

Event

Social Media

Krystal Biotech Inc. shares rise amid strong Biotechnology sector gains and positive social media discussions, with Q2 FY2026 earnings expected on August 3.

27 lip 2026, 22:02 UTC

Social Media

Shares of Krystal Biotech are lower in after-market hours, despite discussions of potential catalysts and an upcoming earnings report on August 3.

24 lip 2026, 19:11 UTC

Krystal Biotech Inc shares are higher today, despite broader market weakness. The stock has seen increased trading activity since Thursday's close.

23 lip 2026, 10:01 UTC

Krystal Biotech Inc shares are higher in pre-market hours, following a slight after-market increase on Wednesday. No specific news was identified for this movement.

22 lip 2026, 19:26 UTC

Krystal Biotech Inc shares are lower today amid a broader market decline, with no specific company news identified to explain the movement.

21 lip 2026, 18:36 UTC

News

Social Media

Krystal Biotech Inc shares are lower today amid trading volatility, despite a planned inclusion in the S&P MidCap 400 on July 24.

20 lip 2026, 21:21 UTC

News

Krystal Biotech Inc. will replace Taylor Morrison in the S&P MidCap 400 on July 24, 2026. The stock is lower in after-hours trading.

Peer Comparison

Price change

Krystal Biotech Inc Forecast

Price Target

By TipRanks

23.76% upside

12 Months Forecast

Average 403.2 USD 23.76%

High 474 USD

Low 361 USD

Based on 6 Wall Street analysts offering 12 month price targets forKrystal Biotech Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

6 ratings

Buy

Hold

Sell

Based on 6 analysts giving stock ratings to Krystal Biotech Inc - Dist in the past 3 months.

Sentiment

By Acuity

323 / 340 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Krystal Biotech Inc

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.